First Quadrant L P CA decreased its position in shares of Endo International PLC (NASDAQ:ENDP) by 6.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,052,695 shares of the company’s stock after selling 147,661 shares during the period. First Quadrant L P CA owned about 0.92% of Endo International PLC worth $22,929,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Norges Bank purchased a new position in shares of Endo International PLC during the fourth quarter valued at $26,929,000. Macquarie Group Ltd. boosted its stake in shares of Endo International PLC by 132.1% in the fourth quarter. Macquarie Group Ltd. now owns 6,500 shares of the company’s stock valued at $107,000 after buying an additional 3,700 shares during the last quarter. Americafirst Capital Management LLC bought a new stake in shares of Endo International PLC during the first quarter valued at approximately $286,000. Hartford Investment Management Co. bought a new stake in shares of Endo International PLC during the first quarter valued at approximately $1,363,000. Finally, Nationwide Fund Advisors boosted its stake in shares of Endo International PLC by 400.0% in the first quarter. Nationwide Fund Advisors now owns 343,874 shares of the company’s stock valued at $3,838,000 after buying an additional 275,101 shares during the last quarter. 93.00% of the stock is owned by institutional investors.
Endo International PLC (NASDAQ:ENDP) traded up 0.53% on Friday, hitting $7.59. 8,959,667 shares of the company’s stock were exchanged. The company’s 50-day moving average price is $10.93 and its 200-day moving average price is $11.55. The company’s market cap is $1.69 billion. Endo International PLC has a 12-month low of $7.41 and a 12-month high of $24.93.
Endo International PLC (NASDAQ:ENDP) last posted its quarterly earnings results on Tuesday, August 8th. The company reported $0.93 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.19. Endo International PLC had a negative net margin of 126.93% and a positive return on equity of 37.58%. The firm had revenue of $875.73 million for the quarter, compared to analyst estimates of $832.66 million. During the same quarter last year, the firm posted $0.86 earnings per share. Endo International PLC’s revenue for the quarter was down 4.9% compared to the same quarter last year. Analysts forecast that Endo International PLC will post $3.51 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Endo International PLC (NASDAQ:ENDP) Position Decreased by First Quadrant L P CA” was originally posted by BNB Daily and is the sole property of of BNB Daily. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.baseball-news-blog.com/2017/08/14/endo-international-plc-nasdaqendp-shares-sold-by-first-quadrant-l-p-ca-updated-updated-updated.html.
ENDP has been the topic of several research analyst reports. Mizuho reiterated a “buy” rating and issued a $19.00 price target (up previously from $18.00) on shares of Endo International PLC in a research note on Thursday, May 25th. Vetr upgraded shares of Endo International PLC from a “hold” rating to a “buy” rating and set a $11.34 target price on the stock in a research report on Tuesday, May 9th. Deutsche Bank AG decreased their target price on shares of Endo International PLC from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, July 7th. Morgan Stanley decreased their target price on shares of Endo International PLC from $12.00 to $8.00 and set an “equal weight” rating on the stock in a research report on Thursday. Finally, ValuEngine lowered shares of Endo International PLC from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Three investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $14.86.
In other news, COO Terrance J. Coughlin acquired 20,000 shares of the company’s stock in a transaction dated Thursday, August 10th. The shares were bought at an average price of $7.70 per share, for a total transaction of $154,000.00. Following the completion of the purchase, the chief operating officer now directly owns 181,369 shares of the company’s stock, valued at approximately $1,396,541.30. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 0.50% of the company’s stock.
Endo International PLC Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.